Rebound Watch! (OTC:BSEM)

BSEM: PROFITABLE, AUDITED, AND BUILDING NASDAQ-READY MOMENTUM IN NEXT-GEN MEDTECH!

BioStem Technologies Inc. is shifting from overlooked small-cap to serious MedTech contender, stacking seven straight profitable quarters, newly audited financials, and a $40M acquisition that expands its hospital footprint and revenue base. 

This isn’t early-stage speculation anymore—it’s a business tightening operations, scaling clinically validated tech, and positioning for a potential Nasdaq uplisting, with analysts already pointing to a $25.50 target!!

After a recent pullback, momentum is starting to stabilize again, with price action hinting at a possible rebound toward the $5 area if sentiment continues to rebuild. 

Between disciplined profitability, expanding clinical adoption of BioREtain® technology, and increasing institutional readiness, BSEM is starting to look like a transition story from small-cap volatility to structured MedTech growth—and that shift is exactly what the market may reprice fast when it sticks.

(OTC: BSEM) — LFG!!!! 🚀
 

Full report Here 

👇

BioStem Technologies, Inc. (OTCQB: BSEM) kicked off this year with a major strategic move by acquiring BioTissue Holdings’ surgical and wound care business in a deal valued at up to $40 million. 

The acquisition, which includes the established Neox® and Clarix® product lines, expands BioStem’s reach into hospital, outpatient, and ambulatory surgery settings and positions the company to address high-value segments like surgical wounds, burns, trauma, and soft-tissue repair. BioTissue contributed $29 million in 2025 revenue, and integrating these assets is expected to accelerate BioStem’s growth, diversify revenue streams, and strengthen its commercial footprint. 

The company has maintained seven consecutive profitable quarters, reported $10.5 million in revenue in its most recent quarter, and holds $16 million in cash, highlighting financial stability and a scalable business model uncommon among small-cap regenerative medicine peers.

BioStem’s proprietary BioREtain® technology underpins its clinical differentiation, with Level 1 randomized trial data showing a 53% probability of wound closure in diabetic foot ulcers compared to 31% under standard care. 

Leveraging FDA-endorsed Bayesian statistical methods, the technology supports physician adoption, reimbursement, and value-based outcomes. With the BioTissue integration, BioStem estimates a total addressable market of $300–$350 million and has already achieved strong early traction, including 40% year-over-year unit growth. 

Looking ahead, the company targets a Nasdaq uplisting in mid-2026, which could broaden institutional ownership and enhance liquidity. Analysts, including Zacks Small Cap Research, highlight BioStem’s profitability, clinical validation, and expanding market access as key drivers, marking BSEM as a compelling small-cap MedTech investment with a sustainable trajectory for growth and shareholder value.

The company will release its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026, and will host a conference call and webcast at 4:30 PM ET. Keep an eye out!

Could another price target increase be on the way from Zack’s?

Read more about BSEM here: Huge Alerts

Disclaimer

Hugealerts.com and Tradingwire.com are owned by Sideways Frequencey LLC (“Sideways Frequency”). Press releases, research reports, company profiles and other investor relations materials, publications or presentations, including web content (investor awareness services) released by Hugealerts.com and Tradingwire.com are based on publicly available data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Furthermore, some of the content contained in our publications and websites may contain forward-looking statements found in information made publicly available by the companies we highlight. This forward looking information fits within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 including statements regarding future possible events, expected continual growth of a company, the potential value of its securities, and look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. We therefore strongly encourage that you visit and review any and all financial information made publicly available by highlighted companies.
Any opinions expressed in Hugealerts.com and Tradingwire.com reports, company profiles, or other investor relations materials and presentations are subject to change, are expressed and given as of the date of publication, and we disclaim any obligation to advise you of any change in any information contained herein.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, Hugealerts.com,Tradingwire.com and their affiliates, specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. Hugealerts.com, Tradingwire.com and their affiliates are not responsible for any gains or losses that result from the opinions expressed in press releases, on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission (“SEC”) at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. and/or the British Columbia Securities Commission (“BCSC”) at https://www.bcsc.bc.ca/.


Income Disclosure

Sideways Frequency has been retained by Biostem Technologies (OTC:BSEM)and has received cash compensation of $3,891,500.00 to perform promotional and advertising services for a limited time. This agreement has been ongoing since September 2023 and is related to the engagement of investor awareness services for Biostem Technologies (OTC:BSEM). Sideways Frequency, Hugealerts.com, Tradingwire.com and their partners and affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.


Sideways Frequency LLC and its affiliates may buy and sell shares of securities or options and warrants of the companies mentioned in this publication or website at any time but are not and will not at any time become affiliates or owners of more than 5% of the issued and outstanding stock of the highlighted companies.


Sideways Frequency and its beneficial owners and affiliates, including Hugealerts.com and Tradingwire.com own shares in Biostem Technologies (OTC:BSEM)


Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. Sideways Frequency, Hugealerts.com, Tradingwire.com and their investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services based on the publicly available information of our clients and prepared by our partners. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Biostem Technologies (OTC:BSEM).


 

1389 Center Dr
Park City UT 84098
USA

Unsubscribe   |   Change Subscriber Options